Navigation Links
Hyperion Therapeutics Secures $40 Million In Series B Round
Date:9/5/2007

SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswire/ -- Hyperion Therapeutics, a biopharmaceutical company focused on the development and commercialization of gastrointestinal and hepatology therapies for the treatment of Urea Cycle Disorders (UCD) and Hepatic Encephalopathy (HE), today announced a $40 million Series B financing. Leading the round was Sofinnova Ventures, with equal commitments by Highland Capital Partners and NEA, all of Menlo Park, CA. WRF Capital of Seattle, WA also participated.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070905/AQW076LOGO )

"We are pleased with the investors' confidence in Hyperion and our team," said Chris Rivera, President and CEO of Hyperion. "The funding will allow us to complete the licensing deal with Medicis Pharmaceutical Corporation (see press release dated August 28, 2007), build out our management team, advance our clinical trials in UCD and HE, and begin the U.S. promotion of the only two FDA-approved compounds for the treatment of UCD, AMMONUL(R) (sodium phenylacetate and sodium benzoate) Injection 10%/10% and BUPHENYL(R) (sodium phenylbutyrate). We look forward to making an immediate impact on patients through efforts to increase the diagnosis, awareness and treatment of UCD with these life-saving drugs."

"The unmet medical need for patients with Urea Cycle Disorders and Hepatic Encephalopathy remain significant," said James Healy, MD, Ph.D, and General Partner of Sofinnova Ventures. "Hyperion is committed to improving the treatment options for these patients."

In response to the announcement of Hyperion's collaboration with Medicis Pharmaceutical Corporation, Cynthia Le Mons, Executive Director of the National Urea Cycle Disorders Foundation commented, "We are excited about the attention and focus the Hyperion team will bring to increasing UCD diagnosis and improving patients' treatment options. We look
'/>"/>

SOURCE Hyperion Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. TrafficCast secures $2M from Phenomenelle Angels, NEW Capital Fund
3. Perscitus Biosciences secures $250K Commerce loan
4. ProCertus BioPharm secures $2.3M in financing
5. Mirus Bio secures $900K grant to develop research tool
6. BioSystem Development secures angel funding
7. TrafficCast secures $1 million line of credit
8. Medical College secures $9.7M research grant
9. Wausau start up secures $560K for GPS maps
10. Platypus Technologies secures $450K SBIR grant
11. nPoint Secures Second Round of Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Product and ... very low abundance and are often “lost in ... time-consuming. , Join presenters Dr. Rowel Tobias, Senior ... John Anders, Head of Quality at Nanotherapeutics, Inc., ... that can speed detection and quantitation while achieving ...
(Date:7/10/2014)... Understanding the need for better quality and higher ... that currently exists in this area, ChanTest has recently ... validated ion channel and GPCR cell lines. ChanTest’s ... channels control many critical physiological functions throughout the body. ... to treat a variety of human diseases. , ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
(Date:7/10/2014)... 10, 2014 OMICS Group’s 5th International ... 18-20 August, 2014 at Double Tree by Hilton Beijing, ... developments in Analytical & Bioanalytical research methods only to ... on this occasion, Dr. Srinubabu Gedela, MD of OMICS ... is a remarkable one in bringing a unique and ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, ... and bioimplants processed from human amniotic membrane, announced ... Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders ... Petit, Chairman and CEO, William C. Taylor, President ...
... and TORONTO, Dec. 1, 2011 Generex Biotechnology Corporation ... on the status of the clinical and regulatory ... insulin spray product. Work has been ... analyses), and revising all of the extant Generex ...
... Calif., Dec. 1, 2011  VIVUS, Inc. (NASDAQ: VVUS ... present an overview of the company at the 2011 Deutsche ... place at the Four Seasons Hotel, Boston, MA on Tuesday, ... and 30-day archive of the presentation will be available at ...
Cached Biology Technology:Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program 2Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program 3Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program 4VIVUS to Present at the Deutsche Bank BioFEST Conference 2VIVUS to Present at the Deutsche Bank BioFEST Conference 3
(Date:7/11/2014)... German . ... refraction of X-rays through a specimen instead of attenuation ... are often of much higher quality than those based ... Franz Pfeiffer are particularly interested in developing new approaches ... phase-contrast imaging. One main goal is to make this ...
(Date:7/11/2014)... National Institute of Standards and Technology (NIST) need ... effectively, they often prove that necessity is truly ... recently for M. Lorna De Leoz and Stephen ... of glycomics. Glycomics is the study of the ... attached to proteins and lipids and influence cellular ...
(Date:7/11/2014)... China Researchers from Salk Institute for Biological Studies, ... evaluated the safety and reliability of the existing ... new method, TALEN-HDAdV, which could significantly increased gene-correction ... This study published online in Cell Stell ... stem cell-based gene therapy. , The combination of ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... target for a drug seems very promising on paper; ... of telomerase inhibitors,to treat cancer; they are supposed to ... cells. Yet, something in the cell,seems to block their ... do then? Scrap the project? Look for something,else? Hell ...
... in humans in forests between Gabon and the Republic ... animal carcasses, according to a study by the Wildlife ... the February edition of the journal Emerging Infectious Diseases, ... Ebola between 2001 and 2003 produced positive results, and ...
... by human activity and the extinction of species around ... warns a Canadian zoologist. This ecological damage also endangers ... , Dr. Daniel (Dan) Brooks, a parasitologist at the ... is linked to the emergence of new human and ...
Cached Biology News:Combination therapy boosts effectiveness of telomere-directed cancer cell death 2Study Links Ebola Outbreaks To Animal Carcasses 2Ecological destruction fuels emerging diseases 2
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
...
... genetically encoded fluorescent sensor capable for high ... one of the main ROS generated by ... fluorescent protein inserted into the regulatory domain ... demonstrates submicromolar affinity to H2O2 and at ...
Alexa Fluor 647 anti-mouse Qa-2...
Biology Products: